Michigan-based Esperion on Oct. 18 announced a plan to reduce the company’s overall workforce by 40 percent and significantly decrease operational expenses in fiscal years 2021 and 2022 to optimize long-term growth.
If you are not happy with the results below please do another search
50 search results for:
Coronavirus vaccines are known to be less protective in people with the blood cancer multiple myeloma, such as former U.S. Secretary of State Colin Powell, who died on Oct. 18 of complications from Covid-19 despite being fully vaccinated. Additionally, in a paper in the journal Stem Cell Reports, researchers said numerous businesses have made unsubstantiated and inaccurate claims about supposed stem cell products to treat Covid-19.
The U.S. Food and Drug Administration greenlit a new indication for Gilead Sciences’ drug Biktarvy for pediatric patients with HIV who are virologically suppressed or new to antiretroviral therapy.
Vertex Pharmaceuticals announced positive Day 90 data from the first patient in the company’s Phase I/II study of VX-880 in type 1 diabetes (T1D). The therapy is a stem cell-derived, fully differentiated pancreatic islet cell replacement therapy.
Omeros, MannKind-United Therapeutics, and Revance Therapeutics were issued Complete Response Letters from the U.S. Food and Drug Administration.
Two years after spinning out from Japan’s Takeda, Phathom Pharmaceuticals is primed to take the company’s acid blocker to the U.S. market with another successful trial.
Valneva SE on Oct. 18 said the company’s experimental Covid-19 vaccine demonstrated efficacy “at least as good, if not better” than AstraZeneca’s shot in a late-stage trial comparing the two, with significantly fewer adverse side effects.
Oyster Point Pharma Inc.’s treatment for dry eye disease became the first U.S. approved nasal spray for the chronic condition on Oct. 18, sending the drug developer’s shares higher.
A late-stage trial of Biogen Inc.’s experimental treatment for an inherited form of amyotrophic lateral sclerosis (ALS) failed to reach the study’s main goal, but secondary measures and biomarkers showed favorable trends, the company said on Oct. 17.
The Greater Than One (GTO) Group announced the introduction of a new operating model to better serve clients outside the United States. Referred to as OUS (Outside United States) On-Demand, the new model will bring the same level of service innovation and value creation abroad as US-based clients experience today.